Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Innodata Inc (INOD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Innodata IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Innodata Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Innodata Inc trades at $63.17 (market cap $2.03B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 65.4× Innodata Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.

INODVRTX
Market Cap
$2.03B$132.79B
Sector
TechnologyHealth
52-Week High
$121.50$529.65
52-Week Low
$34.45$376.62
Enterprise Value
$1.79B$126.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Innodata Inc

INOD trades at $62.33, down 4.81% over 24 hours, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.41 versus $0.21 expected, driven by 58% revenue growth and AI demand expansion. Valuation ratios remain elevated, with a P/E of 48.24 and P/S of 6.79, reflecting high growth expectations. Recent news highlights AI-driven growth and leadership transition plans.

Outlook is positive due to robust AI momentum and earnings beats, but risks include premium valuation and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside from current levels. Investors should weigh growth potential against execution risks in a competitive AI services market.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

About Innodata Inc

Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.

Read more on INOD

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX